Concepts (188)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Yersinia pestis | 11 | 2021 | 35 | 3.060 |
Why?
|
| Polyribonucleotide Nucleotidyltransferase | 6 | 2013 | 6 | 1.950 |
Why?
|
| Plague | 8 | 2021 | 25 | 1.860 |
Why?
|
| Yersinia | 4 | 2013 | 5 | 1.370 |
Why?
|
| Anti-Bacterial Agents | 6 | 2024 | 415 | 1.340 |
Why?
|
| Klebsiella pneumoniae | 3 | 2021 | 26 | 1.290 |
Why?
|
| Dust | 3 | 2021 | 55 | 1.250 |
Why?
|
| RNA Helicases | 3 | 2013 | 19 | 1.190 |
Why?
|
| Endoribonucleases | 3 | 2013 | 24 | 1.180 |
Why?
|
| Plague Vaccine | 3 | 2021 | 4 | 1.170 |
Why?
|
| Multienzyme Complexes | 3 | 2013 | 69 | 1.160 |
Why?
|
| Weightlessness | 3 | 2014 | 27 | 1.150 |
Why?
|
| Virulence Factors | 5 | 2013 | 119 | 1.110 |
Why?
|
| Virulence | 15 | 2021 | 238 | 1.090 |
Why?
|
| Pseudomonas aeruginosa | 2 | 2018 | 62 | 1.080 |
Why?
|
| Escherichia coli | 3 | 2018 | 461 | 0.970 |
Why?
|
| Bacterial Proteins | 6 | 2013 | 580 | 0.970 |
Why?
|
| Stress, Physiological | 4 | 2014 | 170 | 0.940 |
Why?
|
| Gram-Negative Bacteria | 2 | 2014 | 27 | 0.820 |
Why?
|
| Serratia marcescens | 1 | 2023 | 3 | 0.810 |
Why?
|
| Eukaryota | 1 | 2023 | 20 | 0.800 |
Why?
|
| Biofilms | 4 | 2023 | 178 | 0.770 |
Why?
|
| Klebsiella | 1 | 2021 | 3 | 0.710 |
Why?
|
| Stress, Mechanical | 2 | 2012 | 162 | 0.680 |
Why?
|
| Yersinia pseudotuberculosis | 3 | 2012 | 7 | 0.680 |
Why?
|
| Epithelial Cells | 3 | 2018 | 426 | 0.620 |
Why?
|
| Eukaryotic Cells | 1 | 2018 | 36 | 0.580 |
Why?
|
| Cold Temperature | 3 | 2013 | 41 | 0.560 |
Why?
|
| Bacteria | 3 | 2021 | 285 | 0.560 |
Why?
|
| Enterococcus faecalis | 1 | 2018 | 44 | 0.550 |
Why?
|
| Oxidative Stress | 4 | 2023 | 990 | 0.550 |
Why?
|
| Aeromonas hydrophila | 2 | 2013 | 4 | 0.520 |
Why?
|
| Environmental Exposure | 2 | 2017 | 247 | 0.520 |
Why?
|
| Air Microbiology | 1 | 2015 | 15 | 0.480 |
Why?
|
| Coculture Techniques | 3 | 2023 | 105 | 0.470 |
Why?
|
| Gram-Negative Bacterial Infections | 2 | 2014 | 28 | 0.460 |
Why?
|
| Gram-Positive Bacteria | 1 | 2014 | 18 | 0.440 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2014 | 20 | 0.440 |
Why?
|
| Air Pollutants | 1 | 2015 | 127 | 0.430 |
Why?
|
| Immune Evasion | 1 | 2013 | 17 | 0.420 |
Why?
|
| Mutation | 4 | 2013 | 1169 | 0.420 |
Why?
|
| Ofloxacin | 3 | 2012 | 7 | 0.410 |
Why?
|
| Animals | 22 | 2024 | 16695 | 0.410 |
Why?
|
| Bacterial Toxins | 1 | 2013 | 50 | 0.410 |
Why?
|
| Macromolecular Substances | 1 | 2012 | 95 | 0.380 |
Why?
|
| Protein Subunits | 1 | 2012 | 93 | 0.380 |
Why?
|
| Ketolides | 1 | 2011 | 1 | 0.360 |
Why?
|
| Humans | 21 | 2024 | 42163 | 0.360 |
Why?
|
| Ribonucleases | 1 | 2010 | 32 | 0.340 |
Why?
|
| Bacterial Infections | 1 | 2010 | 44 | 0.330 |
Why?
|
| Space Flight | 1 | 2009 | 18 | 0.320 |
Why?
|
| Hela Cells | 4 | 2013 | 370 | 0.310 |
Why?
|
| Gene Expression Regulation, Bacterial | 5 | 2013 | 168 | 0.300 |
Why?
|
| Mice | 14 | 2016 | 6490 | 0.290 |
Why?
|
| Microbial Sensitivity Tests | 3 | 2021 | 232 | 0.280 |
Why?
|
| Macrophages | 6 | 2016 | 515 | 0.280 |
Why?
|
| Mice, Inbred BALB C | 3 | 2014 | 686 | 0.230 |
Why?
|
| Exoribonucleases | 1 | 2004 | 10 | 0.230 |
Why?
|
| Catalytic Domain | 1 | 2004 | 118 | 0.220 |
Why?
|
| Hydrogen Peroxide | 2 | 2017 | 193 | 0.220 |
Why?
|
| China | 2 | 2021 | 233 | 0.210 |
Why?
|
| Cross Infection | 1 | 2024 | 47 | 0.210 |
Why?
|
| Antibodies, Bacterial | 2 | 2021 | 117 | 0.190 |
Why?
|
| Manganese | 1 | 2023 | 89 | 0.180 |
Why?
|
| Zinc | 1 | 2023 | 130 | 0.180 |
Why?
|
| Lead | 1 | 2023 | 101 | 0.180 |
Why?
|
| Bacterial Outer Membrane Proteins | 2 | 2012 | 58 | 0.180 |
Why?
|
| Weightlessness Simulation | 2 | 2012 | 26 | 0.170 |
Why?
|
| Vaccines, Attenuated | 1 | 2021 | 75 | 0.170 |
Why?
|
| Metals, Heavy | 1 | 2021 | 69 | 0.170 |
Why?
|
| Disease Models, Animal | 7 | 2016 | 1554 | 0.160 |
Why?
|
| Cell Proliferation | 2 | 2023 | 1420 | 0.150 |
Why?
|
| Recombinant Proteins | 2 | 2012 | 522 | 0.140 |
Why?
|
| HT29 Cells | 1 | 2017 | 60 | 0.140 |
Why?
|
| Environmental Microbiology | 1 | 2017 | 27 | 0.130 |
Why?
|
| Gastrointestinal Tract | 1 | 2017 | 67 | 0.130 |
Why?
|
| Trifluoperazine | 1 | 2016 | 5 | 0.130 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 2016 | 8 | 0.130 |
Why?
|
| Salmonella Infections | 1 | 2016 | 16 | 0.120 |
Why?
|
| Pregnenediones | 1 | 2016 | 5 | 0.120 |
Why?
|
| Commiphora | 1 | 2016 | 5 | 0.120 |
Why?
|
| Lung | 1 | 2018 | 484 | 0.120 |
Why?
|
| Polynucleotide Adenylyltransferase | 1 | 2015 | 3 | 0.120 |
Why?
|
| RNA, Small Nucleolar | 1 | 2015 | 4 | 0.120 |
Why?
|
| Air Pollution, Indoor | 1 | 2015 | 50 | 0.110 |
Why?
|
| RNA Processing, Post-Transcriptional | 1 | 2015 | 30 | 0.110 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2016 | 147 | 0.110 |
Why?
|
| Particulate Matter | 1 | 2015 | 80 | 0.110 |
Why?
|
| Lipopolysaccharides | 2 | 2014 | 235 | 0.110 |
Why?
|
| Adenosine Triphosphatases | 1 | 2015 | 83 | 0.110 |
Why?
|
| Cell Line | 1 | 2018 | 1416 | 0.110 |
Why?
|
| Caco-2 Cells | 1 | 2014 | 59 | 0.110 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 2015 | 110 | 0.110 |
Why?
|
| Microscopy, Fluorescence | 2 | 2012 | 254 | 0.110 |
Why?
|
| Caenorhabditis elegans | 1 | 2014 | 78 | 0.100 |
Why?
|
| Pore Forming Cytotoxic Proteins | 1 | 2013 | 6 | 0.100 |
Why?
|
| Uterus | 1 | 2014 | 57 | 0.100 |
Why?
|
| Rotation | 1 | 2013 | 27 | 0.100 |
Why?
|
| Drug Resistance, Microbial | 1 | 2013 | 26 | 0.100 |
Why?
|
| Immunization, Passive | 1 | 2012 | 19 | 0.100 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 2012 | 33 | 0.100 |
Why?
|
| Molecular Imaging | 1 | 2012 | 30 | 0.100 |
Why?
|
| Lipoproteins | 1 | 2012 | 68 | 0.100 |
Why?
|
| Antigens, Bacterial | 1 | 2013 | 144 | 0.100 |
Why?
|
| Female | 8 | 2016 | 24018 | 0.100 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2014 | 188 | 0.090 |
Why?
|
| Host-Pathogen Interactions | 1 | 2013 | 203 | 0.090 |
Why?
|
| Peptides | 1 | 2015 | 357 | 0.090 |
Why?
|
| Bioterrorism | 1 | 2011 | 20 | 0.090 |
Why?
|
| Guinea Pigs | 1 | 2011 | 144 | 0.090 |
Why?
|
| Saccharomyces cerevisiae | 2 | 2009 | 199 | 0.080 |
Why?
|
| Phenotype | 1 | 2013 | 774 | 0.080 |
Why?
|
| Rats | 3 | 2012 | 3701 | 0.080 |
Why?
|
| Antineoplastic Agents | 1 | 2016 | 979 | 0.070 |
Why?
|
| Yersinia Infections | 1 | 2007 | 2 | 0.070 |
Why?
|
| Genes, Bacterial | 1 | 2007 | 92 | 0.060 |
Why?
|
| Cells, Cultured | 1 | 2010 | 1617 | 0.060 |
Why?
|
| Yersinia pseudotuberculosis Infections | 1 | 2006 | 3 | 0.060 |
Why?
|
| Protein Transport | 1 | 2007 | 295 | 0.060 |
Why?
|
| Biomedical Research | 1 | 2011 | 467 | 0.060 |
Why?
|
| Mice, Inbred C57BL | 1 | 2011 | 1804 | 0.060 |
Why?
|
| Brain | 1 | 2014 | 1452 | 0.060 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2006 | 74 | 0.060 |
Why?
|
| Neoplasms | 1 | 2016 | 1341 | 0.060 |
Why?
|
| Quorum Sensing | 1 | 2024 | 14 | 0.050 |
Why?
|
| Agriculture | 1 | 2024 | 65 | 0.050 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2024 | 88 | 0.050 |
Why?
|
| Gene Deletion | 2 | 2013 | 168 | 0.050 |
Why?
|
| AIDS Vaccines | 1 | 2002 | 25 | 0.050 |
Why?
|
| Cities | 1 | 2021 | 78 | 0.040 |
Why?
|
| Environmental Monitoring | 1 | 2021 | 226 | 0.040 |
Why?
|
| Texas | 1 | 2021 | 428 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2021 | 845 | 0.040 |
Why?
|
| Doxapram | 1 | 2016 | 1 | 0.030 |
Why?
|
| Amoxapine | 1 | 2016 | 3 | 0.030 |
Why?
|
| Salmonella typhimurium | 1 | 2016 | 40 | 0.030 |
Why?
|
| Resins, Plant | 1 | 2016 | 5 | 0.030 |
Why?
|
| Plant Gums | 1 | 2016 | 7 | 0.030 |
Why?
|
| Prescription Drugs | 1 | 2016 | 32 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2016 | 153 | 0.030 |
Why?
|
| HIV-1 | 1 | 2002 | 747 | 0.030 |
Why?
|
| High-Throughput Screening Assays | 1 | 2016 | 72 | 0.030 |
Why?
|
| Small Molecule Libraries | 1 | 2016 | 60 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2016 | 362 | 0.030 |
Why?
|
| Two-Hybrid System Techniques | 1 | 2015 | 51 | 0.030 |
Why?
|
| Neovascularization, Pathologic | 1 | 2016 | 137 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2016 | 339 | 0.030 |
Why?
|
| Molecular Structure | 1 | 2016 | 560 | 0.030 |
Why?
|
| Genetic Complementation Test | 1 | 2013 | 57 | 0.030 |
Why?
|
| Animal Structures | 1 | 2013 | 21 | 0.030 |
Why?
|
| Gentamicins | 1 | 2012 | 10 | 0.020 |
Why?
|
| Plasminogen Activators | 1 | 2012 | 4 | 0.020 |
Why?
|
| Peptide Hydrolases | 1 | 2013 | 44 | 0.020 |
Why?
|
| Immune Sera | 1 | 2012 | 56 | 0.020 |
Why?
|
| Animals, Outbred Strains | 1 | 2012 | 2 | 0.020 |
Why?
|
| Cell Survival | 1 | 2016 | 934 | 0.020 |
Why?
|
| Vaccines, Synthetic | 1 | 2012 | 78 | 0.020 |
Why?
|
| Immunization | 1 | 2012 | 93 | 0.020 |
Why?
|
| Luciferases | 1 | 2012 | 70 | 0.020 |
Why?
|
| Genes, Reporter | 1 | 2012 | 148 | 0.020 |
Why?
|
| Locomotion | 1 | 2013 | 104 | 0.020 |
Why?
|
| DNA, Bacterial | 1 | 2013 | 207 | 0.020 |
Why?
|
| Protein Binding | 1 | 2015 | 1076 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2012 | 411 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2013 | 508 | 0.020 |
Why?
|
| Motor Activity | 1 | 2014 | 438 | 0.020 |
Why?
|
| Hippocampus | 1 | 2014 | 591 | 0.020 |
Why?
|
| Sex Factors | 1 | 2014 | 1008 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2013 | 1559 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2016 | 2598 | 0.020 |
Why?
|
| Inflammation | 1 | 2014 | 729 | 0.020 |
Why?
|
| Pregnancy | 1 | 2014 | 1737 | 0.020 |
Why?
|
| Apoptosis | 1 | 2016 | 1541 | 0.020 |
Why?
|
| HIV Infections | 1 | 2002 | 2535 | 0.020 |
Why?
|
| Phagocytes | 1 | 2006 | 7 | 0.020 |
Why?
|
| Lethal Dose 50 | 1 | 2006 | 32 | 0.020 |
Why?
|
| Colony Count, Microbial | 1 | 2006 | 67 | 0.020 |
Why?
|
| Cytoskeleton | 1 | 2006 | 111 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 1 | 2006 | 207 | 0.010 |
Why?
|
| Retroviridae Infections | 1 | 2002 | 4 | 0.010 |
Why?
|
| Vaccines, DNA | 1 | 2002 | 24 | 0.010 |
Why?
|
| Vaccines, Subunit | 1 | 2002 | 34 | 0.010 |
Why?
|
| Cats | 1 | 2002 | 80 | 0.010 |
Why?
|
| Primates | 1 | 2002 | 38 | 0.010 |
Why?
|
| Time Factors | 1 | 2006 | 1848 | 0.010 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2002 | 65 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2002 | 249 | 0.010 |
Why?
|
| Male | 1 | 2014 | 22779 | 0.010 |
Why?
|